{
    "hands_on_practices": [
        {
            "introduction": "The modern classification of pituitary adenomas has shifted from a simple description of hormone production to a more fundamental approach based on cellular lineage. This practice challenges you to think like a pathologist by using lineage-defining transcription factors—$Pit-1$, $T-PIT$, and $SF-1$—as the primary basis for classification. Understanding this hierarchical approach is crucial for accurately identifying adenomas, especially those that are clinically \"silent\" or produce minimal hormones .",
            "id": "4386052",
            "problem": "A surgical pathology service aims to standardize classification of pituitary adenomas using a minimal immunohistochemistry panel consisting of lineage transcription factors Pituitary-specific positive transcription factor one (Pit-1, also known as POU class one homeobox one), T-box transcription factor nineteen (T-PIT, also known as TBX nineteen), and Steroidogenic factor one (SF-1, also known as Nuclear receptor subfamily five group A member one), along with hormone stains for Growth Hormone (GH), Prolactin (PRL), Thyroid-Stimulating Hormone (TSH), Adrenocorticotropic Hormone (ACTH), Follicle-Stimulating Hormone (FSH), and Luteinizing Hormone (LH). From a first-principles perspective, lineage transcription factors specify cell identity upstream of hormone synthesis, and immunostaining detects protein expression present at the time of fixation. The goal is to construct a decision algorithm that minimizes misclassification, particularly in tumors with limited or absent hormone immunoreactivity. Which proposed decision algorithm most consistently reflects pituitary lineage biology and yields correct classification across functioning and non-functioning adenomas?\n\nA. Begin with hormone immunostains. If any hormone is positive, assign the corresponding adenoma subtype directly. If all hormones are negative, designate a null cell adenoma and omit lineage transcription factor stains unless clinical or radiographic features suggest hormone excess.\n\nB. Begin with lineage transcription factor immunostains. If T-PIT is positive, classify as corticotroph lineage, using ACTH staining to distinguish functioning from silent lesions without changing lineage. If SF-1 is positive, classify as gonadotroph lineage, using FSH, LH, or glycoprotein alpha-subunit stains if available to support secretion but not to override lineage. If Pit-1 is positive, classify as Pit-1 lineage and then use GH, PRL, and TSH immunostains to subclassify as somatotroph, lactotroph, thyrotroph, or Pit-1-positive plurihormonal adenoma when more than one Pit-1-lineage hormone is expressed. If all three lineage transcription factors are negative and all hormones are negative, designate a true null cell adenoma.\n\nC. Begin with lineage transcription factor immunostains. If SF-1 is positive, classify as a somatotroph or lactotroph adenoma depending on GH versus PRL positivity; if Pit-1 is positive, classify as gonadotroph depending on FSH or LH positivity; reserve T-PIT only for confirming ACTH-positive tumors. If all hormones are negative, call a null cell adenoma even if a lineage transcription factor is positive.\n\nD. Begin with Pit-1. If Pit-1 is positive, call lactotroph; if GH is positive regardless of Pit-1, call somatotroph; consider TSH adenomas as SF-1 lineage when TSH is positive; use T-PIT only when ACTH is strongly positive, and otherwise classify ACTH-negative tumors without T-PIT as null cell to avoid overcalling lineage in silent adenomas.",
            "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\nThe problem provides the following information for standardizing the classification of pituitary adenomas:\n- **Objective**: To construct a decision algorithm that minimizes misclassification, particularly in tumors with limited or absent hormone immunoreactivity.\n- **Tools (Immunohistochemistry Panel)**:\n    - **Lineage Transcription Factors**:\n        - Pituitary-specific positive transcription factor one (`Pit-1`, also known as `POU1F1`)\n        - T-box transcription factor nineteen (`T-PIT`, also known as `TBX19`)\n        - Steroidogenic factor one (`SF-1`, also known as `NR5A1`)\n    - **Hormone Stains**:\n        - Growth Hormone (`GH`)\n        - Prolactin (`PRL`)\n        - Thyroid-Stimulating Hormone (`TSH`)\n        - Adrenocorticotropic Hormone (`ACTH`)\n        - Follicle-Stimulating Hormone (`FSH`)\n        - Luteinizing Hormone (`LH`)\n- **First Principles**:\n    1. Lineage transcription factors specify cell identity upstream of hormone synthesis.\n    2. Immunostaining detects protein expression present at the time of fixation.\n- **Question**: Which proposed decision algorithm most consistently reflects pituitary lineage biology and yields correct classification across functioning and non-functioning adenomas?\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated against the validation criteria.\n\n- **Scientifically Grounded**: The problem is based on the established principles of pituitary gland developmental biology and the modern pathological classification of pituitary neuroendocrine tumors (PitNETs), as codified in the World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors. The specified transcription factors (`Pit-1`, `T-PIT`, `SF-1`) are indeed the master regulators for the three primary anterior pituitary cell lineages:\n    - `Pit-1` specifies the somatotroph, lactotroph, and thyrotroph lineages.\n    - `T-PIT` specifies the corticotroph lineage.\n    - `SF-1` specifies the gonadotroph lineage.\nThe premise that lineage factors are upstream of hormone synthesis is a fundamental concept in molecular and developmental biology. The distinction between functioning and non-functioning (or \"silent\") adenomas is a core clinical and pathological concept. The problem is factually and scientifically sound.\n\n- **Well-Posed**: The problem is well-posed. It provides a clear objective (minimize misclassification by adhering to biological hierarchy), a set of tools (the IHC panel), and a guiding principle (lineage factors are primary). The task is to evaluate four given algorithms against this framework, which allows for a unique, correct answer to be determined based on the provided information.\n\n- **Objective**: The problem is stated in objective, technical language devoid of ambiguity or subjective claims. The terms used are standard in the field of pathology and endocrinology.\n\nThe problem does not exhibit any flaws such as scientific unsoundness, incompleteness, contradiction, or ambiguity. It presents a standard, real-world problem in diagnostic pathology that can be solved by applying the provided first principles.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. The solution process will now proceed.\n\n## SOLUTION DERIVATION\n\nThe core principle for a robust classification system, as stated in the problem, is that **lineage transcription factors specify cell identity upstream of hormone synthesis**. This dictates a hierarchical approach. The primary determinant of an adenoma's classification must be its lineage, as defined by the expression of the master transcription factors (`Pit-1`, `T-PIT`, `SF-1`). The expression of downstream hormones (`GH`, `PRL`, `TSH`, `ACTH`, `FSH`, `LH`) is a secondary characteristic used for sub-classification (e.g., distinguishing a functioning adenoma from a silent one) but should not override the lineage-based classification.\n\nA correct algorithm must therefore:\n1.  Begin by assessing the expression of the three lineage-defining transcription factors: `T-PIT`, `SF-1`, and `Pit-1`.\n2.  Assign the tumor to a specific lineage based on the transcription factor that is positive. The correct associations are:\n    - **`T-PIT` expression**: Defines a **corticotroph lineage** adenoma.\n    - **`SF-1` expression**: Defines a **gonadotroph lineage** adenoma.\n    - **`Pit-1` expression**: Defines a **`Pit-1` lineage** adenoma.\n3.  Use hormone immunostains to sub-classify the adenoma *within* its defined lineage.\n    - If a **corticotroph** adenoma (`T-PIT` positive) is also `ACTH` positive, it can be further described in that manner (e.g., functioning or densely granulated). If it is `ACTH` negative or sparsely positive, it is classified as a silent corticotroph adenoma. The classification remains corticotroph adenoma.\n    - If a **gonadotroph** adenoma (`SF-1` positive) shows `FSH` and/or `LH` expression, this confirms its potential for secretion. If it is negative for these hormones, it is a silent gonadotroph adenoma. The classification remains gonadotroph adenoma.\n    - If a **`Pit-1` lineage** adenoma (`Pit-1` positive) is stained for hormones, the results determine the subtype: somatotroph (`GH` positive), lactotroph (`PRL` positive), thyrotroph (`TSH` positive), or plurihormonal if multiple are positive. An adenoma that is `Pit-1` positive but negative for all related hormones is a silent `Pit-1` lineage adenoma, not a null cell adenoma.\n4.  A **true null cell adenoma** is defined by the absence of differentiation along any of the three main lineages. Therefore, it must be negative for all three transcription factors (`T-PIT`, `SF-1`, `Pit-1`) and also negative for all hormones.\n\nThis hierarchical approach is crucial for achieving the stated goal of minimizing misclassification, especially for tumors with little to no hormone expression, which older, hormone-only-based schemes would have erroneously classified as \"null cell adenomas.\"\n\n## OPTION-BY-OPTION ANALYSIS\n\n**A. Begin with hormone immunostains. If any hormone is positive, assign the corresponding adenoma subtype directly. If all hormones are negative, designate a null cell adenoma and omit lineage transcription factor stains unless clinical or radiographic features suggest hormone excess.**\n\n- **Analysis**: This algorithm directly violates the stated first principle by prioritizing hormone expression (a downstream, variable feature) over lineage transcription factors (the upstream, defining feature). It fails the primary objective of correctly classifying tumors with limited hormone reactivity, as it would mislabel all silent adenomas (e.g., a silent gonadotroph adenoma that is `SF-1` positive but `FSH`/`LH` negative) as \"null cell adenomas\". This represents an outdated approach.\n- **Verdict**: **Incorrect**.\n\n**B. Begin with lineage transcription factor immunostains. If T-PIT is positive, classify as corticotroph lineage, using ACTH staining to distinguish functioning from silent lesions without changing lineage. If SF-1 is positive, classify as gonadotroph lineage, using FSH, LH, or glycoprotein alpha-subunit stains if available to support secretion but not to override lineage. If Pit-1 is positive, classify as Pit-1 lineage and then use GH, PRL, and TSH immunostains to subclassify as somatotroph, lactotroph, thyrotroph, or Pit-1-positive plurihormonal adenoma when more than one Pit-1-lineage hormone is expressed. If all three lineage transcription factors are negative and all hormones are negative, designate a true null cell adenoma.**\n\n- **Analysis**: This algorithm perfectly implements the hierarchical, principle-based logic derived above. It correctly starts with lineage factors, uses the correct factor-to-lineage associations, employs hormones for secondary sub-classification without overriding the primary lineage, and accurately defines a true null cell adenoma. This approach is consistent with modern pituitary tumor classification and fulfills all requirements of the problem statement.\n- **Verdict**: **Correct**.\n\n**C. Begin with lineage transcription factor immunostains. If SF-1 is positive, classify as a somatotroph or lactotroph adenoma depending on GH versus PRL positivity; if Pit-1 is positive, classify as gonadotroph depending on FSH or LH positivity; reserve T-PIT only for confirming ACTH-positive tumors. If all hormones are negative, call a null cell adenoma even if a lineage transcription factor is positive.**\n\n- **Analysis**: This algorithm contains multiple fundamental errors in biological mapping. It incorrectly associates `SF-1` with somatotrophs/lactotrophs (which are `Pit-1` lineage) and incorrectly associates `Pit-1` with gonadotrophs (which are `SF-1` lineage). Furthermore, the statement that a hormone-negative but transcription factor-positive tumor should be called a \"null cell adenoma\" directly contradicts the purpose of using lineage markers to avoid such misclassifications.\n- **Verdict**: **Incorrect**.\n\n**D. Begin with Pit-1. If Pit-1 is positive, call lactotroph; if GH is positive regardless of Pit-1, call somatotroph; consider TSH adenomas as SF-1 lineage when TSH is positive; use T-PIT only when ACTH is strongly positive, and otherwise classify ACTH-negative tumors without T-PIT as null cell to avoid overcalling lineage in silent adenomas.**\n\n- **Analysis**: This algorithm is a collection of incorrect and illogical steps. It oversimplifies the `Pit-1` lineage to only lactotrophs. It violates the lineage-first principle by classifying based on `GH` regardless of `Pit-1`. It makes a factually incorrect association between `TSH` adenomas and the `SF-1` lineage (they are `Pit-1` lineage). The logic for using `T-PIT` is flawed and would lead to misclassification of silent corticotroph adenomas. The entire procedure is inconsistent with pituitary biology.\n- **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Once an adenoma is identified, the next critical step is to determine its functional status and its impact on the patient. This exercise puts you in the role of an endocrinologist investigating a suspected corticotroph adenoma, the cause of Cushing's disease. You will apply core principles of endocrine feedback by interpreting results from a dexamethasone suppression test and a specialized localization procedure, inferior petrosal sinus sampling (IPSS), to confirm the diagnosis .",
            "id": "4386000",
            "problem": "A patient with suspected hyperpituitarism due to a corticotroph microadenoma (a pituitary adenoma arising from adrenocorticotropic hormone-producing cells) is evaluated using suppression and localization tests grounded in hypothalamic-pituitary-adrenal axis physiology. In a normal hypothalamic-pituitary-adrenal axis, a synthetic glucocorticoid such as dexamethasone suppresses cortisol production through negative feedback on corticotrophs; failure of suppression indicates autonomous adrenocorticotropic hormone production. Additionally, pituitary adrenocorticotropic hormone excess can be localized by demonstrating a central-to-peripheral gradient via inferior petrosal sinus sampling.\n\nUse the following well-tested observations to interpret the data:\n1. After an overnight low-dose dexamethasone suppression test of $1~\\text{mg}$, normal morning serum cortisol suppresses to $\\leq 1.8~\\mu\\text{g}/\\text{dL}$.\n2. Inferior petrosal sinus sampling (IPSS) compares adrenocorticotropic hormone (ACTH) levels in the inferior petrosal sinuses (IPS) to peripheral blood. A pituitary source is supported if the inferior petrosal sinus to peripheral gradient is $\\geq 2$ at baseline or $\\geq 3$ after corticotropin-releasing hormone (CRH) stimulation.\n\nData:\n- Pre-dexamethasone morning serum cortisol: $24.5~\\mu\\text{g}/\\text{dL}$.\n- Post-overnight $1~\\text{mg}$ dexamethasone morning serum cortisol: $22.1~\\mu\\text{g}/\\text{dL}$.\n- Baseline ACTH (pg/mL): peripheral $65$, right IPS $195$, left IPS $140$.\n- Post-CRH ACTH (pg/mL): peripheral $85$, right IPS $510$, left IPS $255$.\n\nDefine the diagnostic indicator $I$ as follows: $I = 1$ if the findings are consistent with a corticotroph microadenoma (i.e., failure of low-dose dexamethasone suppression and a pituitary source indicated by the IPSS gradient thresholds above), and $I = 0$ otherwise.\n\nCompute $I$. Express the final answer as the single number $I$. No rounding is required, and no units should be included in the final answer box.",
            "solution": "The problem requires the computation of a diagnostic indicator, $I$, based on a set of clinical data and established criteria for diagnosing hyperpituitarism secondary to a corticothorph microadenoma. The value of $I$ is set to $1$ if the data are consistent with the diagnosis and $0$ otherwise. This determination rests on two key physiological tests: the low-dose dexamethasone suppression test and inferior petrosal sinus sampling (IPSS). We must evaluate the results of both tests against the provided criteria.\n\nFirst, let us validate the problem statement.\nThe givens are:\n1.  Normal suppression threshold for an overnight $1~\\text{mg}$ low-dose dexamethasone test: post-test morning serum cortisol $\\leq 1.8~\\mu\\text{g}/\\text{dL}$.\n2.  Inferior petrosal sinus sampling (IPSS) criterion for a pituitary source: An inferior petrosal sinus (IPS) to peripheral (P) ACTH gradient (IPS:P) $\\geq 2$ at baseline OR an IPS:P gradient $\\geq 3$ after corticotropin-releasing hormone (CRH) stimulation.\n3.  Patient's pre-dexamethasone morning serum cortisol: $24.5~\\mu\\text{g}/\\text{dL}$.\n4.  Patient's post-dexamethasone morning serum cortisol: $22.1~\\mu\\text{g}/\\text{dL}$.\n5.  Patient's baseline ACTH levels: peripheral $65$ pg/mL, right IPS $195$ pg/mL, left IPS $140$ pg/mL.\n6.  Patient's post-CRH ACTH levels: peripheral $85$ pg/mL, right IPS $510$ pg/mL, left IPS $255$ pg/mL.\n7.  The definition of the indicator: $I = 1$ if there is failure of low-dose dexamethasone suppression AND the IPSS indicates a pituitary source; $I = 0$ otherwise.\n\nThe problem is scientifically grounded in the established pathophysiology and diagnostic algorithms of endocrinology. The provided data and criteria are standard and clinically realistic. The problem is well-posed, providing all necessary information to compute a single, unique value for $I$. The language is objective and precise. Therefore, the problem is deemed valid and a solution may be pursued.\n\nWe will now evaluate the two conditions required for $I=1$.\n\n**Condition 1: Failure of Low-Dose Dexamethasone Suppression**\n\nThe criterion for normal suppression is a post-dexamethasone morning serum cortisol level less than or equal to $1.8~\\mu\\text{g}/\\text{dL}$. The patient's measured post-dexamethasone cortisol is $22.1~\\mu\\text{g}/\\text{dL}$. We compare the patient's result to the threshold:\n$$22.1~\\mu\\text{g}/\\text{dL} > 1.8~\\mu\\text{g}/\\text{dL}$$\nSince the patient's cortisol level is not suppressed to the required level, this test result indicates a failure of suppression. This finding is consistent with autonomous production of ACTH, as seen in a corticotroph adenoma. Thus, the first condition for $I=1$ is met.\n\n**Condition 2: Pituitary Source Indicated by IPSS**\n\nThe IPSS test supports a pituitary source of ACTH if either the baseline or post-CRH stimulation gradient meets its respective threshold. The gradient is defined as the ratio of the higher of the two IPS ACTH concentrations to the peripheral ACTH concentration.\n\nLet us evaluate the baseline gradient, $G_{base}$.\nThe peripheral ACTH level at baseline is $A_{P,base} = 65$ pg/mL.\nThe IPS ACTH levels at baseline are $A_{R-IPS,base} = 195$ pg/mL and $A_{L-IPS,base} = 140$ pg/mL.\nWe use the maximum of the two IPS values: $A_{IPS,max,base} = \\max(195, 140) = 195$ pg/mL.\nThe baseline gradient is:\n$$G_{base} = \\frac{A_{IPS,max,base}}{A_{P,base}} = \\frac{195}{65} = 3$$\nThe criterion for a positive baseline test is $G_{base} \\geq 2$. We check our result against this criterion:\n$$3 \\geq 2$$\nThis condition is satisfied. Since the diagnostic criterion for IPSS is disjunctive (i.e., the baseline OR post-CRH test must be positive), meeting the baseline criterion is sufficient to confirm a pituitary source.\n\nFor pedagogical completeness, we will also evaluate the post-CRH gradient, $G_{CRH}$.\nThe peripheral ACTH level post-CRH is $A_{P,CRH} = 85$ pg/mL.\nThe IPS ACTH levels post-CRH are $A_{R-IPS,CRH} = 510$ pg/mL and $A_{L-IPS,CRH} = 255$ pg/mL.\nWe use the maximum of the two post-CRH IPS values: $A_{IPS,max,CRH} = \\max(510, 255) = 510$ pg/mL.\nThe post-CRH gradient is:\n$$G_{CRH} = \\frac{A_{IPS,max,CRH}}{A_{P,CRH}} = \\frac{510}{85} = 6$$\nThe criterion for a positive post-CRH test is $G_{CRH} \\geq 3$. We check our result against this criterion:\n$$6 \\geq 3$$\nThis condition is also satisfied. Thus, the IPSS results unequivocally indicate a central (pituitary) source of ACTH excess. The second condition for $I=1$ is met.\n\n**Computation of I**\n\nThe diagnostic indicator $I$ is equal to $1$ if and only if both conditions are met.\n- Condition 1 (failure of suppression) is met.\n- Condition 2 (pituitary source on IPSS) is met.\nSince both logical propositions are true, their conjunction is true.\nTherefore, the value of the indicator is $I = 1$.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "In clinical practice, diagnosis is often a process of accumulating evidence rather than relying on a single definitive test. This problem introduces a powerful quantitative tool from evidence-based medicine to diagnose acromegaly, a condition caused by a growth hormone-secreting adenoma. You will learn how to use pre-test probability and likelihood ratios to combine results from multiple diagnostic tests, providing a more robust and statistically sound conclusion about the likelihood of disease .",
            "id": "4386073",
            "problem": "A patient with suspected somatotroph pituitary adenoma causing acromegaly undergoes evaluation rooted in the pathophysiology that excessive growth hormone (GH) from a pituitary adenoma elevates hepatic production of insulin-like growth factor $1$ (IGF-$1$), and that in healthy individuals, GH secretion is suppressible by oral glucose due to normal hypothalamic-pituitary regulation. The collected data are: fasting GH $8~\\text{ng/mL}$, nadir GH $3~\\text{ng/mL}$ measured at $2$ hours after a $75$ g oral glucose load, and IGF-$1$ elevated to $3$ standard deviations above the age-adjusted mean. In this endocrinology referral setting, the pre-test probability of acromegaly is $0.20$. For this population, the following empirically derived positive likelihood ratios are available: IGF-$1$ at $\\geq 3$ standard deviations above the mean has LR$+$ $12$, nadir GH $\\geq 1~\\text{ng/mL}$ at $2$ hours after a $75$ g glucose load has LR$+$ $8$, and fasting GH $\\geq 7~\\text{ng/mL}$ has LR$+$ $2$. Treat the three test results as conditionally independent pieces of evidence given disease status and apply the appropriate combination of likelihood ratios to update the diagnostic probability of acromegaly in this patient. Express the final probability as a decimal without a percentage sign, and round your answer to four significant figures.",
            "solution": "The problem requires the calculation of a post-test probability of acromegaly given a pre-test probability and the results of three diagnostic tests. The method to be used is Bayesian updating, employing the odds-likelihood ratio formulation.\n\nFirst, let us formalize the given information.\nLet $A$ be the event that the patient has acromegaly.\nThe pre-test probability of acromegaly is given as $P(A) = 0.20$.\n\nThe odds of an event are defined as the ratio of the probability of the event occurring to the probability of the event not occurring. The pre-test odds, $O_{pre}$, are therefore:\n$$O_{pre} = \\frac{P(A)}{P(A^c)} = \\frac{P(A)}{1 - P(A)}$$\nSubstituting the given value:\n$$O_{pre} = \\frac{0.20}{1 - 0.20} = \\frac{0.20}{0.80} = 0.25$$\n\nThe problem provides results for three tests and their corresponding positive likelihood ratios (LR$+$, or $\\text{LR}_+$). A positive likelihood ratio for a test result $E$ is defined as the ratio of the probability of that result in a patient with the disease to the probability of the same result in a patient without the disease:\n$$\\text{LR}_+ = \\frac{P(E|A)}{P(E|A^c)}$$\n\nThe patient's test results and the associated likelihood ratios are:\n1.  Insulin-like growth factor $1$ (IGF-$1$) elevated to $3$ standard deviations above the mean. The corresponding likelihood ratio is $\\text{LR}_{+, IGF-1} = 12$.\n2.  Nadir growth hormone (GH) of $3~\\text{ng/mL}$ after a $75$ g oral glucose load. Since $3~\\text{ng/mL} \\geq 1~\\text{ng/mL}$, this result corresponds to a likelihood ratio of $\\text{LR}_{+, OGTT} = 8$.\n3.  Fasting GH of $8~\\text{ng/mL}$. Since $8~\\text{ng/mL} \\geq 7~\\text{ng/mL}$, this result corresponds to a likelihood ratio of $\\text{LR}_{+, FastingGH} = 2$.\n\nThe problem states that these three test results are to be treated as conditionally independent given the disease status. When evidence is conditionally independent, the combined likelihood ratio for the set of results is the product of the individual likelihood ratios.\n$$\\text{LR}_{combined} = \\text{LR}_{+, IGF-1} \\times \\text{LR}_{+, OGTT} \\times \\text{LR}_{+, FastingGH}$$\nSubstituting the given values:\n$$\\text{LR}_{combined} = 12 \\times 8 \\times 2 = 192$$\n\nBayes' theorem in odds form states that the post-test odds ($O_{post}$) are the product of the pre-test odds and the likelihood ratio for the observed evidence.\n$$O_{post} = O_{pre} \\times \\text{LR}_{combined}$$\nUsing our calculated values:\n$$O_{post} = 0.25 \\times 192 = 48$$\n\nFinally, we must convert the post-test odds back to a probability. The relationship between probability $P$ and odds $O$ is given by:\n$$P = \\frac{O}{1 + O}$$\nTherefore, the post-test probability of acromegaly, $P(A|E)$, is:\n$$P(A|E) = \\frac{O_{post}}{1 + O_{post}} = \\frac{48}{1 + 48} = \\frac{48}{49}$$\n\nTo provide the answer as a decimal rounded to four significant figures, we perform the division:\n$$\\frac{48}{49} \\approx 0.9795918367...$$\nRounding to four significant figures gives $0.9796$.",
            "answer": "$$\\boxed{0.9796}$$"
        }
    ]
}